Table 2 Demographics, cardiovascular risk factors, and disease characteristics relationship with apolipoprotein C-III
Apolipoprotein C-III, mg/dl | ||
|---|---|---|
Beta coef. (95%CI) | ||
Age, years | − 0.03 (− 0.08–0.03) | 0.35 |
Women, n (%) | − 0.82 (− 2.20–0.56) | 0.25 |
BMI, kg/m2 | 0.00 (− 0.03–0.03) | 0.89 |
Abdominal circumference, cm | 0.07 (0.03–0.11) | 0.001 |
Cardiovascular data | ||
CV risk factors, n (%) | ||
Current smoker | − 1.11 (− 2.34–0.13) | 0.079 |
Obesity | 0.98 (− 0.14–2.10) | 0.087 |
Hypertension | − 0.26 (− 1.39–0.86) | 0.64 |
Diabetes mellitus | – | |
Statins, n (%) | 0.39 (− 0.74–1.53) | 0.50 |
Lipids | ||
Total cholesterol, mg/dl | 0.00 (− 0.01–0.02) | 0.75 |
Triglycerides, mg/dl | 0.01 (0.00–0.02) | 0.001 |
HDL cholesterol, mg/dl | 0.03 (− 0.06–0.01) | 0.15 |
LDL cholesterol, mg/dl | 0.00 (− 0.02–0.01) | 0.57 |
LDL:HDL cholesterol ratio | 0.21 (− 0.36–0.77) | 0.47 |
Non-HDL cholesterol, mg/dl | 0.01 (− 0.01–0.02) | 0.38 |
Lipoprotein (a), mg/dl | 0.00 (− 0.01–0.01) | 0.76 |
Apolipoprotein A1, mg/dl | − 0.01 (− 0.02–0.01) | 0.42 |
Apolipoprotein B, mg/dl | 0.00 (− 0.01–0.01) | 0.66 |
Apo B:Apo A ratio | 0.12 (− 1.97–2.20) | 0.91 |
Disease-related data | ||
Disease duration, years | − 0.06 (− 0.11–0.00) | 0.048 |
CRP at time of study, mg/l | 0.04 (0.01–0.08) | 0.021 |
ESR at time of study, mm/ 1º h | 0.03 (0.00–0.06) | 0.021 |
Rheumatoid factor, n (%) | − 0.34 (− 1.54–0.86) | 0.58 |
ACPA, n (%) | 0.56 (− 0.52–1.64) | 0.31 |
DAS28-ESR | 0.55 (0.18–0.93) | 0.004 |
DAS28-PCR | 0.33 (− 0.15–0.82) | 0.18 |
SDAI | 0.02 (− 0.02–0.07) | 0.34 |
CDAI | 0.01 (− 0.06–0.08) | 0.79 |
History of extraarticular manifestations, n (%) | − 0.76 (− 2.61–1.10) | 0.42 |
Erosions, n (%) | − 1.59 (–2.67 to − 0.52) | 0.004 |
Current drugs, n (%) | ||
Prednisone | − 0.05 (− 1.13–1.03) | 0.93 |
Prednisone doses, mg/day | − 0.33 (− 0.54 to − 0.11) | 0.004 |
NSAIDs | − 0.28 (− 1.31–0.75) | 0.59 |
DMARDs | − 1.35 (− 2.81–0.11) | 0.071 |
Methotrexate | − 0.92 (− 2.07–0.23) | 0.12 |
Leflunomide | − 2.21 (− 3.43 to − 0.98) | < 0.001 |
Hydroxychloroquine | − 4.33 (− 5.89 to − 2.78) | < 0.001 |
Salazopyrin | − 4.32 (− 6.24 to − 2.41) | < 0.001 |
Anti TNF therapy | − 0.79 (− 2.05–0.47) | 0.22 |
Tocilizumab | − 0.34 (− 2.40–1.71) | 0.74 |
Rituximab | 1.88 (− 1.67–5.43) | 0.30 |
Abatacept | 1.12 (− 1.86–4.11) | 0.46 |
Baricitinib | − 1.73 (− 5.92–2.46) | 0.42 |
Tofacitinib | − 3.48 (− 6.48–0.52) | 0.022 |